Amgen's Diversification Continues To Pay Off, RBC Says

MT Newswires Live04-03

Amgen's (AMGN) pipeline diversification continues to pay off, improving visibility on out-year growth, RBC Capital Markets said in a Thursday note.

Among the drivers, the report pointed to its established portfolio, the integrated assets Tepezza, Krystexxa, Uplizna, and emerging pipeline including Imdelltra and MariTide.

The report said Repatha, Evenity and Tezspire have all grown between 30% and 50% last year, with Repatha and Evenity still having a long way to go given single-digit penetration in multi-million patient markets.

"AMGN is, in our view, a high quality biotech company on a relative basis as well as from a dividend perspective with steady cash flows and a proven track record," the report said, pointing to general medicines, oncology, immunology & inflammation, and rare disease exposures.

RBC has an outperform rating with a $360 price target.

Price: 347.86, Change: -5.42, Percent Change: -1.53

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment